Note: Ingredients listed on restricted chemical lists
EC/CAS
110-97-4
Name of the chemical
1,1'-iminodipropan-2-ol
Concentration
370-15 1-5
EC/CAS
111-76-2
Name of the chemical
Ethylene glycol monobutyl ether (EGBE)
Concentration
1-5
General Information
Version
4
Revision date
2025-12-20
Product name
POWERCRON BRIGHT RED TINT
1.2.1 Relevant identified uses
Industrial applications
Manufacturer Name
PPG Industries, Inc
Icons in SDS
Company Information
company name
PPG Industries, Inc
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H319
Hazard statements
Code
Statements
H319
Causes serious eye irritation
Section 2
SECTION 2: Hazards identification
Ingredient(s) with unknown acute toxicity
13.4% (oral), 13.4% (dermal), 42.2% (inhalation)
Signal word
Warning
Hazard statements
Causes serious eye irritation.
Prevention
Wear eye or face protection. Wash thoroughly after handling.
Response
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice or attention.
Storage
Not applicable.
Disposal
Not applicable.
Supplemental label elements
Repeated exposure to high vapor concentrations may cause irritation of the respiratory system and permanent brain and nervous system damage. Inhalation of vapor/aerosol concentrations above the recommended exposure limits causes headaches, drowsiness and nausea and may lead to unconsciousness or death. This product either contains formaldehyde or is capable of releasing formaldehyde above 0.5 ppm under certain conditions. Formaldehyde is a known cancer hazard, a skin sensitizer and a respiratory sensitizer. Avoid contact with skin and clothing. Wash thoroughly after handling. Emits toxic fumes when heated.
2.3 Other hazards
Prolonged or repeated contact may dry skin and cause irritation.
2.1 Classification of the substance or mixture
substance or mixture Percentage of the mixture consisting of ingredient(s) of unknown acute toxicity: 13.4% (oral), 13.4% (dermal), 42.2% (inhalation)